Contact lenses can now also treat Glaucoma, a new study shows.
An experimental design of contact lens is said to have shown the release of glaucoma medicines at a steady rate for up to a month. This would help people wearing such contact lenses in achieving dual benefits of corrected vision- temporary (with the lenses on) as well as permanent.
The inventors of the new contact lenses, ophthalmologist Joseph Ciolino and his mentor Daniel Kohane, developed the special design for lenses at Harvard Medical School. The inventors developed the design to help people using traditional eye drops for Glaucoma. Though the most famous form of medication for glaucoma, patients hardly see any benefits or getting any symptomatic relief from the use of eye drops. There’s hardly much motivation left in being compliant with it anymore.
Glaucoma refers to a set of conditions that can cause irreversible blindness if not cured early. Glaucoma is caused as a result of increased fluid pressure in the eye or optical nerve damage.
Early treatment can also reduce vision loss up to a certain extent, most commonly done by the use of eye drops. But the regular use of eye drops is no less than a challenge. Also, even while the drops can minimize further damage to eyes, they cannot repair the damage that has already been done.
This special design of lenses incorporates a structure that could resemble a doughnut stuffed in a pita-pocket- a common glaucoma medicine sandwiched inside the lens.
The innovative design of the lens presents many more potential medical advantages other than improving the condition of glaucoma patients, such as aiding other eye-related problems by delivering antibiotics and other anti-inflammatory drugs to the eye.
The inventors have added that this design is different than other prototyped lenses because of the many-layered structure that allows for the placement of the drug-releasing film between the layers. The other designs in the market mostly use a lens that is pre-dipped in the drug-solution, which then leach-out the drug to the eye on an inconsistent rate.